Abiopharma

🔍 Wickramasinghe Mahes (Director)

Company: SunOpta Inc. (STKL)

Report Date: 2026-05-01

Detailed Transactions and Holdings:

• Sold 51,218 shares of Common Stock (Direct)
  Date: 2026-05-01 | Code: D | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1
• Sold 35,476 shares of Restricted Stock Unit (RSU) (Derivative)
  Date: 2026-05-01 | Code: D | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2, F3, F3, F3

Footnotes:

• F1: Pursuant to the Arrangement Agreement (the "Arrangement Agreement"), dated as of February 6, 2026, by and among SunOpta Inc. ("SunOpta"), Pegasus BidCo B.V. ("Parent") and 2786694 Alberta Ltd. ("Purchaser"), Purchaser acquired all of SunOpta's issued and outstanding common shares in the capital of SunOpta (the "Common Shares") by way of a court-approved statutory plan of arrangement under Section 192 of the Canada Business Corporations Act (the "Arrangement"). At the effective time of the Arrangement (the "Effective Time"), each of SunOpta's issued and outstanding Common Shares were transferred to Purchaser for consideration of $6.50 per share in cash, less applicable withholdings (the "Consideration").
• F2: Each Restricted Stock Unit represents a contingent right to receive one share of STKL common stock.
• F3: At the Effective Time, each restricted stock unit ("RSU") held by the reporting person was surrendered in exchange for, subject to any withholding, a cash payment equal to the Consideration in respect of each Common Share underlying such RSU.